An early clinical trial of BCX4161 in patients with hereditary angioedema compared to treatment with placebo To evaluate the effect of prophylactic BCX4161 as measured by the frequency of attacks in subjects with hereditary angioedema (HAE)

• Country None
• organs None
• Specialty None

Single agent phase II study of Forodesine (BCX1777) in the treatment of cutaneous T-Cell Lymphoma The primary objective is to determine the objective response rate to treatment with oral forodesine in subjects with cutaneous manifestations of CTCL, stages IIb, III and IVa.

• Country None
• organs None
• Specialty None

A phase II/III multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intramuscular peramivir in subjects with uncomplicated acute influenza To evaluate the efficacy of peramivir compared to placebo when administered intramuscularly on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza A.

• Country None
• organs None
• Specialty None

A Phase II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride (BCX-1777) Infusion in Patients with Advanced T-Cell Leukemia with an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use To determine the sustained effectiveness (for a minimum of 28 days) of intravenous (IV) forodesine hydrochloride infusions in patients with advanced T-cell leukemia (precursor T-lymphoblastic leukemia...

• Country None
• organs None
• Specialty None

A placebo controlled trial of of three doses of BCX7353 to evaluate the safety and efficacy in the prevention of attacks in patients with HAE • To evaluate the efficacy of prophylactic BCX7353 at 3 doses over 28 days as measured by the frequency of attacks in subjects with hereditary angioedema (HAE)

• Country None
• organs None
• Specialty None

BioCryst BCX1777-203 : Essai de phase 2 évaluant l’efficacité et la tolérance d’un traitement par forodésine chez des patients ayant un lymphome cutané. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] Single agent phase II study of forodesine (BCX1777) in the treatment of cutaneous T-cell lymphoma.

• Country France
• organs Lymphomes non hodgkinien
• Specialty Chimiothérapie

OPuS-4: An open-label study to evaluate the long-term safety of avoralstat in subjects with hereditary angioedema (HAE) To determine the long-term safety and tolerability of oral avoralstat in subjects with hereditary angioedema (HAE)

• Country None
• organs None
• Specialty None

BCX7353 for the prevention of HAE attacks BCX7353-203 BCX7353 en la prevención de ataques de AEH To evaluate the efficacy of once-daily prophylactic BCX7353 at 3 dose levels as measured by the number of attacks of hereditary angioedema (HAE) observed in patients with HAE enrolled in each treatmen...

• Country None
• organs None
• Specialty None

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Virologic Activity, Safety, and Pharmacodynamics of Intravenous Peramivir for the Treatment of Experimental Influenza To evaluate the virologic activity of peramivir by intravenous administration compared to placebo against experimental challenge with A/Panama/2007/99.

• Country None
• organs None
• Specialty None

A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents who are Hospitalized due to Serious Influenza To evaluate the effect of treatment with peramivir plus standard of care (SOC) compared to placebo plus SOC on time to clinical resolution in adults and adolescents who are hospitalized with influenza...

• Country None
• organs None
• Specialty None